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http://dx.doi.org/10.1016/j.ccell.2015.03.010SUMMARYPhosphoinositide-3-kinase (PI3K)-a inhibitors have shown clinical activity in squamous cell carcinomas
(SCCs) of head and neck (H&N) bearing PIK3CA mutations or amplification. Studying models of therapeutic
resistance, we have observed that SCC cells that become refractory to PI3Ka inhibition maintain PI3K-inde-
pendent activation of the mammalian target of rapamycin (mTOR). This persistent mTOR activation is medi-
ated by the tyrosine kinase receptor AXL. AXL is overexpressed in resistant tumors from both laboratory
models and patients treated with the PI3Ka inhibitor BYL719. AXL dimerizes with and phosphorylates
epidermal growth factor receptor (EGFR), resulting in activation of phospholipase Cg (PLCg)-protein kinase
C (PKC), which, in turn, activates mTOR. Combined treatment with PI3Ka and either EGFR, AXL, or PKC in-
hibitors reverts this resistance.INTRODUCTION
Head and neck (H&N) and esophageal squamous cell carci-
nomas (SCCs) are among the most common types of cancer,
with an annual worldwide incidence rate of 600,000 and
400,000, respectively (Jemal et al., 2011). Despite the effortsSignificance
The therapeutic options for patients with H&N and esophagea
frequent mutations and amplifications of PIK3CA, which encod
hibitors under clinical development in these tumors has been
clinical resistance eventually develops, and dissecting the
improved treatment approaches. Here, we show that the activ
AXL, which, upon interacting with EGFR, initiates a survival m
the basis to explore dual PI3Ka and EGFR blockade in patiento improve their outcome, the 5-year survival rate is only
50% in H&N cancer and 10% in esophageal cancer (Jemal
et al., 2011; Kamangar et al., 2006). Cetuximab, a monoclonal
antibody targeting epidermal growth factor receptor (EGFR),
is currently the only approved targeted agent for the therapy of
H&NSCC, with only amodest improvement in the overall survivall SCCs are limited, and survival is poor. These tumors have
es the p110a subunit of PI3Ka. Clinical activity of PI3Ka in-
reported. However, as with many other targeted therapies,
underlying mechanisms driving resistance could lead to
ity of these compounds may be limited by the presence of
echanism resulting in drug resistance. Our work provides
ts with H&N and esophageal SCC.
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of these patients (Baselga et al., 2005; Bonner et al., 2006; Ver-
morken et al., 2008). No targeted therapy is currently available
for esophageal SCC.
The phosphoinositide-3-kinase (PI3K) pathway plays a key
role in the regulation of multiple cellular events, including cell
growth, proliferation, cell cycle progression, and survival (Vi-
vanco and Sawyers, 2002). The PI3K family of enzymes is
divided into three main classes (classes I–III), with class I being
the most often implicated in human cancer (Engelman, 2009;
Hennessy et al., 2005). Class I PI3K comprises a regulatory sub-
unit (p85), which mediates binding to membrane growth factor
receptors, and one of four catalytic subunits (p110a, -b, -g,
or -d), which are responsible for the activity of the enzyme (Engel-
man, 2009). Activating mutations of PI3KCA have been found in
6%–20% of H&N and 4%–10% of esophageal SCCs, with the
hot-spot E542K, E545K, and H1047R substitutions being the
most common (Agrawal et al., 2011; Lui et al., 2013; Song
et al., 2014; Stransky et al., 2011). Moreover, increase in PIK3CA
copy number has been found in up to 30% of H&N and 40% of
esophageal tumors and is associated with poor prognosis
(Agrawal et al., 2011; Akagi et al., 2009; Lin et al., 2014; Song
et al., 2014; Stransky et al., 2011; Suda et al., 2012).
Tumors with activating alterations in PIK3CA aremore respon-
sive to therapy with specific PI3Ka inhibitors (Elkabets et al.,
2013; Fritsch et al., 2014; Furet et al., 2013). In the first-in-human
clinical trial of the PI3Ka specific inhibitor BYL719 in solid tumors
(NCT01387321), we have recently reported that eight patients
with H&N tumors harboring PI3KCA mutations had a clinical
response to therapy (D.J., H.A. Burris, M. Schuler, J.H.M.
Schellens, J. Berlin, R. Seggewiss-Bernhardt, M. Gil-Martin,
A. Gupta, J.R., J. Tabernero, F. Janku, H. Rugo, D. Bootle,
C. Quadt, C. Coughlin, D. Demanse, L. Blumenstein, and J.B.,
2014, Annals of Oncology, abstract). These are encouraging
early results and support the clinical development of these
agents in patients with H&N SCC tumors. Given the similarities
between H&N and esophageal SCCs, this approach should
also be explored in esophageal SCC. However, as with other tar-
geted therapies, we can anticipate that their efficacy will be
limited by the development of acquired resistance. In fact, all
the responding patients in our clinical trial with BYL719 eventu-
ally became refractory to treatment. In this work, we investigated
the primary and acquired mechanisms of resistance to PI3Ka in-
hibitors in H&N and esophageal SCC tumors. Our ultimate goal
was to design treatment strategies that could prevent or delay
the appearance of resistance and that would be potentially appli-
cable to the treatment of patients.
RESULTS
Persistent mTOR Activation Defines Acquired
Resistance to BYL719 in SCC
In an initial approach to explore the sensitivity of SCC to the
PI3Ka inhibitor BYL719, we measured, in a panel of 58 SCC
cell lines, the median inhibitory concentration (IC50) after
5 days of treatment. Some cell lines displayed absolute resis-
tance at doses up to 10 mM, while the remaining cells showed
a gradient of sensitivity to BYL719. The concentration of 10 mM
was chosen to define resistance because it is the highest achiev-
able concentration, albeit briefly, in the plasma of patients and,534 Cancer Cell 27, 533–546, April 13, 2015 ª2015 Elsevier Inc.therefore, likely to be clinically relevant (D.J., H.A. Burris,
M. Schuler, J.H.M. Schellens, J. Berlin, R. Seggewiss-Bernhardt,
M. Gil-Martin, A. Gupta, J.R., J. Tabernero, F. Janku, H. Rugo,
D. Bootle, C. Quadt, C. Coughlin, D. Demanse, L. Blumenstein,
and J.B., 2014, Annals of Oncology, abstract). In terms of
PIK3CA status and sensitivity to BYL719, 76% (19/25) of
cell lines bearing either mutations or amplification (copy num-
ber >4) in PIK3CA were sensitive, while only 48% (16/33) of
cell lines bearing wild-type (WT)-PIK3CA were sensitive (Fig-
ure 1A). PIK3CA mutation/amplification was the only genomic
alteration that predicted sensitivity to BYL719 (Figure S1A).
To study the molecular mechanisms by which acquisition of
resistance to BYL719 emerges, we selected four sensitive cell
lines bearing either amplified or mutated PIK3CA (CAL33,
LB771-HNC, KYSE70, and KYSE180) and exposed them over
time to increasing concentrations of BYL719 until resistance
emerged (Figure 1B; Figures S1B and S1C).
In order to elucidate the underlying mechanisms of resistance,
we first analyzed potential differences of pathway inhibition with
BYL719 between parental cells and their resistant counterparts.
While AKT and its downstream effector, PRAS40, were equally
suppressed by BYL719 treatment in both parental and resistant
cells, mammalian target of rapamycin (mTOR) activity was not
abolished upon PI3Ka inhibition in resistant cells, as indicated
by persistent phosphorylation of its downstream ribosomal pro-
tein S6 (pS6) in residues 235/6 and 240/4 (Figure 1C).
The addition of the allosteric mTORC1 inhibitor RAD001 abol-
ished the phosphorylation of S6 (Figure 1D) and was sufficient to
re-sensitize the resistant cells to BYL719 (Figure S1D). Given that
the mTORC2 complex directly activates AKT, treatment with the
catalytic mTOR inhibitor AZD8055, which targets both mTORC1
and mTORC2, was very effective in suppressing both AKT and
mTORphosphorylation, resulting in strong antiproliferative activ-
ity even when used as a single agent (Figure 1D).
Wewere able to independently demonstrate the causative role
of mTOR in resistance to BYL719 in a synthetic lethality short
hairpin RNA (shRNA) screen for 134 cancer-related genes
performed in three BYL719-resistant cell lines (CAL33R,
KYSE180R, and the intrinsically resistant HSC3) (Elkabets
et al., 2013). We observed that MTOR, which encodes mTOR,
was the top gene that, when knocked down, re-sensitized resis-
tant cells to the antiproliferative activity of BYL719 (Figure 1E;
Figure S1E; Table S1).
Taken together, these results show that SCC cells with ac-
quired resistance to BYL719 maintain mTOR activity and that
pharmacological or shRNA inhibition of mTOR results in re-
sensitization to BYL719.
EGFR Activation Is Sufficient to Limit the Sensitivity to
BYL719 in SCC Cells
We and others have shown that ligand-mediated activation of re-
ceptor tyrosine kinases (RTKs) can rescue the efficacy of a vari-
ety of agents against key signaling pathways (Elkabets et al.,
2013; Harbinski et al., 2012; Straussman et al., 2012; Wilson
et al., 2012). In order to explore whether RTK activation can
sustain mTOR activity in the presence of BYL719 and induce
resistance to this agent in our models, we performed a high-
throughput secretome screen (Harbinski et al., 2012) using the
BYL719-sensitive cell lines CAL33 and SNU1214 (Figure 2A;
Figure 1. PI3K/AKT-Independent mTOR Activation in BYL719-Resistant Cells
(A) Main genetic features and IC50 for BYL719 of 58 cell lines from H&N and esophageal SCC. Amp and Mut, amplification and mutation.
(B) Proliferation (5 days) of four cell lines sensitive to BYL719 in comparison with their resistant counterparts upon increasing doses of BYL719.
(C) Western blot analysis of PI3K/AKT pathway signaling using cell lysates from BYL719-sensitive (S) and BYL719-resistant (R) cells treated with 1 mMBYL719 for
4 hr and the indicated antibodies.
(D)Western blot with the indicated antibodies of protein lysates fromBYL719-resistant cells upon 4 hr of treatment with 100 nMRAD001 or 500 nMAZD8055 with
and without 1 mM BYL719.
(E) Ranking of knockdown genes that re-sensitize resistant cells to BYL719 (Z score).
Data are presented as means ± SEM; p values were calculated using two-tailed Student’s t test. **p < 0.01.
See also Figure S1 and Table S1.
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Figure 2. Role of EGFR in Maintaining
mTOR Activity upon BYL719 Treatment
(A) Results from a secretome screen conducted in
CAL33 cells upon treatment for 4 days with 1 mM
BYL719. Each square represents the average of
three replicates of cells conditioned with the same
ligand. The y axis shows relative cell growth as a
percentage of DMSO.
(B) Heatmap showing the effects of recombinant
ligands in limiting the antiproliferative activity of
1 mMof BYL719 for 6 days in H&N and esophageal
SCC cell lines. Red and orange indicate full and
partial rescue from treatment, respectively.
(C) Western blot with the indicated antibodies of
the CAL33 cell line treated for 4 hr with 1 mM
BYL719, 10 mg/ml cetuximab, and 1 mM
MGCD265 in the presence of 50 ng/ml EGF or
HGF as indicated.
(D) Proliferation (6 days) of CAL33 cells treated as
indicated with 1 mM BYL719, 10 mg/ml cetuximab
(Cetux.), and 1 mM MGCD265 in the presence of
50 ng/ml EGF or HGF.
(E) Western blot with the indicated antibodies of
protein lysates from CAL33R and KYSE180R cells
treated with 1 mM BYL719 in combination with
either 1 mM MGCD265 or 5 mM erlotinib.
(F) Proliferation (5 days) of resistant cell lines
treated with different concentrations of erlotinib or
MGCD265 with or without 1 mM BYL719. Signifi-
canceoferlotinib+BYLversuserlotinib isdisplayed.
Data are presented asmeans± SEM; p valueswere
calculated using two-tailed Student’s t test. **p <
0.01. See also Figure S2 and Table S2.Table S2). Among the over 300 secreted proteins tested,
epidermal growth factor (EGF), heparin-binding EGF (HBEGF)
(both binding EGFR), hepatocyte growth factor (HGF, binding
cMET), fibroblast growth factors (FGFs, binding FGF recep-
tors), and neuregulin (NRG, binding HER3) prevented, to
some degree, BYL719-induced growth inhibition. In order to
study the reproducibility of these results, we tested whether
these ligands could rescue the inhibitory effects of BYL719
in five additional BYL719-sensitive cell lines (one PIK3CA
WT, two PIK3CA mutated, and two PIK3CA amplified). Among
the tested recombinant ligands, only EGF and, to a lesser
extent, HGF could either partially or completely prevent
BYL719 antiproliferative activity in all cell lines (Figure 2B; Fig-
ures S2A and S2B). The same ligands did not prevent BYL719-
induced antiproliferative activity in either breast or ovarian cell
lines, underscoring their lineage specificity for SCC cells (Fig-
ure S2C). The addition of the anti-EGFR antibody cetuximab or
the anti-cMET inhibitor MGCD265 opposed the effects of EGF
or HGF, respectively, and suppressed S6 phosphorylation and536 Cancer Cell 27, 533–546, April 13, 2015 ª2015 Elsevier Inc.re-sensitized cells to BYL719 (Figures 2C
and 2D; Figure S2D). Of note, in LB771-
HNC cells, EGF was more effective than
HGF in maintaining S6 phosphorylation
and inducing proliferation in the presence
of BYL719 (Figure S2D). Next, we tested
whether co-inhibition of EGFR or cMET
with BYL719 was sufficient to reducemTOR activity in cell lines with acquired resistance to BYL719.
TreatmentwithBYL719 in combinationwith erlotinib, an EGFRki-
nase inhibitor, but not withMGCD235 or crizotinib (another cMET
kinase inhibitor) resulted in suppression of S6 phosphorylation
(Figure 2E; Figure S2E). These biochemical effects translated
into superior antiproliferative activity in cells where both PI3Ka
and EGFR were inhibited, compared to the lack of a significant
additive effect when BYL719was combinedwith cMET inhibition
(Figure 2F). These effects seemed to be mediated mainly by
reduction of proliferation (S phase) compared to BYL719 alone
(Figure S2E).
Based on these results, we decided to confirm that activation
of EGFR is sufficient to reverse tumor growth inhibition induced
by treatment with BYL719 in vivo. Animals bearing CAL33-
derived xenografts and implanted with pumps that release re-
combinant human EGF showed a reduced inhibition of tumor
growth upon BYL719 treatment, compared to animals with
pumps releasing vehicle. Furthermore, as we observed in vitro,
treatment with cetuximab re-sensitized the tumors to PI3K
inhibition and induced tumor shrinkage (Figure S2F). Pharmaco-
dynamic studies showed that the addition of EGF induced phos-
phorylation of EGFR, activated the mTOR pathway (indicated by
pS6), and promoted proliferation (Figures S2G and S2H). The
combination of BYL719 and cetuximab prevented EGFR phos-
phorylation and mTOR activation and resulted in decreased pro-
liferation and induction of cell death (Figures S2G and S2H).
Anti-EGFR Treatment Reverses Acquired and Intrinsic
Resistance to PI3Ka Inhibition in SCC
To further characterize the effects of EGFR blockade in reverting
resistance, we conducted a series of studies with the anti-EGFR
monoclonal antibody cetuximab, which prevents ligand binding
to the receptor and is approved for the treatment of H&N SCC.
Like the majority of antibodies, cetuximab is devoid of off-target
effects, even at high doses. In SCC cells with acquired resistance
to BYL719, the addition of cetuximab to BYL719 was superior to
both agents given alone in reducing S6 phosphorylation (Fig-
ure 3A) and in induction of cell death and/or reduction of prolifer-
ation (Figure 3B; Figures S3A and S3B). These results were
confirmed in vivowithKYSE180Rxenograftswhere, asexpected,
the tumors were non-responsive to BYL719 and the combination
of BYL719 and cetuximab was superior to cetuximab alone (Fig-
ure 3C). In these tumors, the combination of cetuximab and
BYL719 was sufficient to block most of the phosphorylation of
S6 (Figure S3C), and this correlated with decreased tumor prolif-
eration and increased cell death (Figure 3D).
A similar antitumor activity of the combination of BYL719 and
cetuximab was observed also in cells with intrinsic resistance to
BYL719, both in vitro (Figure 3E; Table S3) and in vivo (Figure 3F).
Simultaneous suppression of EGFR and PI3Ka resulted in su-
perior activity, compared with that of single-agent treatment,
also in cells intrinsically sensitive to BYL719. Despite both
BYL719 and cetuximab effectively reducing cell viability, the
combinationwas significantly superior to single agent (Figure 3G;
Figure S3D; Table S3). In tumor xenografts, even if treatment
with either BYL719 or cetuximab reduced tumor growth in
BYL719-sensitive models, including H&N patient-derived xeno-
grafts (PDXs) available in our laboratory, the combination re-
sulted in greater tumor inhibition and shrinkage (Figure 3H;
Figure S3E). Pharmacodynamic analysis of KYSE180 xenografts
confirmed that the combination of BYL719 and cetuximab
reduced cell proliferation and induced cell death more effec-
tively, compared to single-agent treatment (Figure S3F).
Although we cannot exclude a priori that some of the antitumor
effects observed with cetuximab were due to antibody-depen-
dent cell cytotoxicity (ADCC), there is ample evidence that inhi-
bition of receptor activation and signaling is responsible for the
antitumor effects of cetuximab (Fan et al., 1993).
In those cases where the combination achieved complete tu-
mor remission (11 of 17 tumors for CAL33 and 8 of 20 tumors
for KYSE180), the tumors did not recur after therapy completion.
This combination therapy showednoappreciable toxicity inmice,
as indicated by their unchanged body weights (Figure S3G).
Upregulation of AXL and Its Interaction with EGFR Are
Associated with Resistance to BYL719
Aiming to investigate the molecular mechanisms leading to
EGFR activation during the acquisition of resistance to PI3Ka in-hibition, we analyzed the transcriptome of KYSE180 and CAL33
cells using RNA sequencing (RNA-seq) and compared it to
their resistant counterparts. A differential expression analysis
was performed to identify genes that were associated with resis-
tance to BYL719. Our analysis was restricted to genes whose
expression varied in the same direction in both cell lines upon
emergence of resistance. We identified 56 and 153 genes that
were upregulated (log of change > 1.2) or downregulated
(log of change < 1.2), respectively, in both KYSE180R and
CAL33R cell lines (Figure 4A; Figure S4A). The most significantly
upregulated gene in the resistant cells was AXL in both cell lines
(Figures 4A; Figure S4B; Table S4). AXL is a membrane-bound
receptor tyrosine kinase that interacts with HER receptors
(Meyer et al., 2013; Paccez et al., 2014) and limits the sensitivity
to anti-EGFR or anti-HER2 therapies (Byers et al., 2013; Liu et al.,
2009; Zhang et al., 2012). Analysis from the The Cancer Genome
Atlas (TCGA) (Cerami et al., 2012) indicated that high expression
of AXL (among the top ten upregulated genes) was associated
with poor prognosis in patients with H&N tumors bearing either
mutations or amplification of PIK3CA (Figures S4C and S4D)
(Cerami et al., 2012). Thus, with our findings, we hypothesized
that overexpression of AXL and its interaction with EGFR could
play a role in mediating resistance to PI3Ka inhibition.
A number of additional observations provided support for the
role of AXL in mediating resistance to PI3Ka inhibition. First,
we confirmed that cells with acquired resistance to BYL719
and xenografts that were initially sensitive but that eventually
escaped BYL719 treatment had higher levels of AXL, compared
to their parental equivalents (Figures 4B and 4C). In addition,
when we examined the basal mRNA levels of AXL in our panel
of 58 cell lines, we observed an inverse correlation between
AXL expression and sensitivity to BYL719 (Figure 4D; Table
S4). This observation was further validated at the protein level
in a smaller cohort of cell lines (Figure 4E).
Next,we investigated the association betweenAXLexpression
and resistance to PI3Ka inhibition in tumors from patients who
participated in the initial clinical study of BYL719 (D.J., H.A. Bur-
ris, M. Schuler, J.H.M. Schellens, J. Berlin, R. Seggewiss-Bern-
hardt, M. Gil-Martin, A. Gupta, J.R., J. Tabernero, F. Janku,
H. Rugo, D. Bootle, C. Quadt, C. Coughlin, D. Demanse, L. Blu-
menstein, and J.B., 2014, Annals of Oncology, abstract). We
were able to obtain high-quality tumor samples from ten SCC
patients (nine with H&N cancer and one with cervical cancer)
treated with BYL719 (one patient was treated with the combina-
tion of BYL719 and theMEK inhibitor MK162) (Table S5). In these
samples collected before initiation of treatment, those tumors
with lower AXL expression had higher shrinkage upon PI3Ka in-
hibition (Figure 4F; Figures S4E and S4F; Table S5). Strikingly,
the five patients with the best responses were the patients with
the lowest levels of AXL detected (Table S5). Moreover, in three
of these patients, we also obtained and analyzed tumor biopsies
obtained at the time of disease progression to BYL719. Two of
the three patients presented a marked increase in AXL levels in
the post-treatment sample when compared with the baseline tu-
mor expression, while no changes were appreciated in the third
patient (Figure 4G; Figure S4F; Table S6). Of note, the post-treat-
ment specimen that did not experience changes in AXL expres-
sion (Patient 6) was obtained from a brain metastasis. Given that
BYL719 does not permeate the blood-brain barrier, it is likely thatCancer Cell 27, 533–546, April 13, 2015 ª2015 Elsevier Inc. 537
Figure 3. Antitumor Activity of BYL719 in Combination with Cetuximab
(A) Western blot with the indicated antibodies of protein lysates from resistant cells treated as indicated with 1 mM BYL719, 5 mg/ml cetuximab (Cetux.), or the
combination.
(B) Proliferation (6 days) of resistant cells treated with 1 mM BYL719, 5 mg/ml cetuximab, or the combination.
(C) Tumor growth of KYSE180R-derived xenografts treated as indicated (n = 6–10 per arm). Significance of combination versus cetuximab is displayed.
(D) KYSE180R-derived xenograft tumors from mice treated as indicated were analyzed for proliferation (Ki67) and apoptosis (TUNEL).
(E) Cell viability (4 days) of 23 cell lines intrinsically resistant to BYL719 treated with 3 mM BYL719, 10 ng/ml cetuximab, or the combination.
(legend continued on next page)
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this lesion was never exposed to pharmacologically meaningful
concentrations of the drug.
Then, we examined the interaction of AXL and EGFR in both
sensitive and resistant cells. The higher levels of AXL in our
resistant models (CAL33R and KYSAE180R) coincided with
increased EGFR and AXL interaction as shown by EGFR-AXL
co-immunoprecipitation (Figure 4H). This interaction was further
validated by an in situ proximity ligation assay, which enabled us
to visualize and quantify the interaction of AXL and EGFR (Fig-
ure 4I) (So¨derberg et al., 2008). The number of AXL/EGFR
complexes, indicated by the red dots, is significantly higher in
resistant cell lines compared to the parental counterpart. Overall,
our data indicate that AXL expression and its interaction with
EGFR are associated with resistance to PI3Ka inhibition.
The AXL/EGFR Interaction Activates mTOR and Limits
Sensitivity to BYL719
In order to assess whether AXL overexpression plays a causative
role in mediating resistance to PI3Ka inhibition, we ectopically
transduced this receptor in two BYL719-sensitive cell lines and
found that forced expression of AXL was sufficient to limit the
sensitivity to BYL719 (Figure 5A). Overexpression of a kinase-
dead version of AXL (Zhang et al., 2012) did not affect BYL719
sensitivity, suggesting that the kinase activity of the receptor is
required to induce resistance to PI3Ka inhibitors (Figure 5A).
Biochemical analysis of these cells indicate that high levels of
WT-AXL was sufficient to prevent BYL719-dependent inhibition
of mTOR but failed to do so when EGFR expression was
concomitantly knocked down (Figure S5A). Moreover, the inhibi-
tion of EGFRwas sufficient to re-sensitizeWT-AXL-overexpress-
ing cells to BYL719 (Figure S5B). Likewise, knocking down the
expression of AXL in cell lines with acquired resistance to
BYL719 re-sensitized the cells to PI3Ka inhibition (Figure 5B).
Pharmacological inhibition of AXL by the small-molecule ATP
competitor R428 (Holland et al., 2010) was sufficient to achieve
greater inhibition of pS6 upon BYL719 treatment (Figures 5C
and 5D; Figure S5C) and enhanced the antiproliferative activity
of BYL719 in resistant cells (Figure 5E; Figure S5D). Co-inhibition
of AXL and PI3Ka in BYL719-sensitive cells resulted in further in-
hibition of pS6 and greater tumor cell growth inhibition (Figures
S5E–S5G), suggesting that even relatively low levels of AXL
may be sufficient to partially counteract the activity of BYL719.
Taken together, these results show that BYL719-resistant
cells display high levels of AXL and the interaction of this recep-
tor with EGFR leads to sustained mTOR activation enabling cells
to overcome PI3Ka inhibition.
AXL/EGFR Binding Activates the PLCg-PKC Signaling
Cascade
Next, we aimed to elucidate the AXL/EGFR downstream
signaling pathway(s) that lead(s) to mTOR activation in the pres-(F) Tumor growth of A253- and HSC3-derived xenografts (intrinsically resistant to
versus cetuximab is displayed.
(G) Cell viability (4 days) of 35 cell lines intrinsically sensitive to BYL719 treated w
(H) Tumor growth of xenograft derived fromBYL719-sensitive cell lines treated as
cetuximab is displayed. For HSC2, the significance of combination versus BYL7
Data are presented as means ± SEM; p value was calculated using two-tailed S
Figure S3 and Table S3.ence of the PI3Ka blockade.Whenwe investigated the activation
status of EGFR in ourmodels, we observed a consistent increase
of EGFR phosphorylation at tyrosine 1173 (and not other tyrosine
residues such as 1068) associatedwith AXL overexpression (Fig-
ure 6A). Tyrosine 1173 in EGFR, when phosphorylated, functions
as a docking site for phospholipase Cg (PLCg) (Chattopadhyay
et al., 1999). PLCg cleaves phosphatidylinositol 4,5-bisphos-
phate (PIP2) at the plasmamembrane, resulting in the production
of the second messengers diacyl glycerol (DAG) and inositol
1,4,5-triphosphate (IP3). DAG activates members of the protein
kinase C (PKC) family at the membrane (Rosse et al., 2010).
The PKC family is a family of serine/threonine kinases capable
of interacting with a plethora of substrates and ultimately leading
to cell proliferation, survival, and migration (Disatnik et al., 1994;
Mochly-Rosen et al., 2012). PKC has also been shown to activate
mTOR in an AKT-independent manner (Fan et al., 2009). Accord-
ingly, the increased EGFR 1173 phosphorylation observed in
our cells with acquired resistance to BYL719 was associated
with the activation of PLCg and PKCz, the member of the PKC
family mostly implicated in mediating EGFR signaling in H&N
cancer (Cohen et al., 2006) (Figure 6A). Inhibition of EGFR by
erlotinib in the presence of BYL719 was sufficient to block the
PLCg/PKC axis in resistant cell lines (Figure 6B).
To elucidate the effect of AXL on EGFR phosphorylation, we
knocked down AXL in resistant cells and observed a specific
reduction in EGFR 1173 phosphorylation (Figure S6A). Similarly,
inhibition of AXL by R428 prevented the specific interaction be-
tween the residue 1173 of EGFRwith AXL, as shown in the immu-
noprecipitation experiment (Figure 6C; Figure S6B) or proximity
ligation assay (Figure S6C). Furthermore, co-treatment with
BYL719 and R428 inhibited PLCg phosphorylation and cooper-
ated in suppressing S6 phosphorylation in cells with acquired
resistance to BYL719 (Figure S6D). These results indicate that
AXL can interact with EGFR in a way that leads to the activation
of the PLC/PKC axis. To investigate the role of PKC as amediator
of mTOR activation, we treated resistant cells with BYL719 in
combination with several inhibitors of PKC. Co-suppression of
PI3Ka and PKC invariably resulted in reduction of S6 phosphory-
lation (Figure6D;FigureS6E). Theseeffectsweredosedependent
and durable in time in both resistant and sensitive cells (Figure 6E;
Figure S6F). As a result, combined PI3Ka and PKC inhibition
(PKC412) resulted in superior antiproliferative activity, compared
to single-agent treatment in both BYL719-resistant and BYL719-
sensitive cells (Figures 6F and 6G; Figures S6G and S6H).
Overall, these data show that upregulation of AXL and its inter-
action with EGFR can sustain mTOR activity in the presence of
PI3K inhibition. AXL transactivates EGFR in a ligand-indepen-
dent manner and induces phosphorylation of EGFR on tyrosine
1173. Such an event results in PLCg and PKC activation that,
in turn, leads to a PI3K/AKT-independent activation of mTOR
(Figure 7).BYL719) treated as indicated (n = 6–10 per arm). Significance of combination
ith 3 mM BYL719, 10 ng/ml cetuximab, or the combination.
indicated (n = 6–10 per arm). For CAL33, the significance of combination versus
19 is displayed.
tudent’s t test. *p < 0.05; **p < 0.01; ***p < 0.005. Scale bar, 100 mm. See also
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Figure 4. Upregulation of AXL in BYL719-Resistant Tumors and Direct Interaction with EGFR
(A) Dot plot analysis from RNA-seq of KYSE180 and CAL33 cells compared to their resistant counterparts.
(B) AXL levels in the indicated sensitive (S) and resistant (R) cell lines treated with 1 mM BYL719.
(C) Tumor growth of KYSE180-derived xenografts treatedwith 50mg/kg BYL719 daily. AXL levels in control tumors (vehicle) and in xenografts after treatment with
BYL719 for 2 months are shown. Scale bar, 100 mm.
(D) Comparison of IC50 between SCC cells with high and low (first vs. fourth quartile) AXL mRNA expression (data extracted from the TCGA).
(E) Baseline AXL expression on a panel of BYL719-sensitive and -resistant cell lines.
(legend continued on next page)
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Figure 5. AXL/EGFR Drives mTOR Activa-
tion and Causes Resistance to BYL719
(A) Cell viability of CAL33 and KYSE70 cells over-
expressing either WT or kinase-dead (KD) AXL
upon treatment with BYL719 (upper panel) and
western blot showing both endogenous and
exogenous expression of AXL (lower panel). EV,
empty vector; HA, hemagglutinin tag.
(B) Cell viability (3 days) of KYSE180R and CAL33R
cells subjected to AXL knockdown and treated as
indicated (upper panel) and western blot showing
AXL knockdown (lower panel). siCT, small inter-
fering control (scrambled) RNA; siAXL, small
interfering RNA targeting AXL.
(C) Western blot with the indicated antibodies of
cell lysates from KYSE180R cells treated for 4 hr
with different concentrations of R428 and 1 mM of
BYL719.
(D) Western blot with the indicated antibodies of
cell lysates from KYSE180R treated with 1 mM
BYL719, 1 mM R428, or the combination at
different time points.
(E) Cell viability (4 days) of cells with acquired
resistance to BYL719 treated with increased con-
centrationsofR428withorwithout 1mMofBYL719.
Data are presented as means ± SEM; p value was
calculated using two-tailed Student’s t test. *p <
0.05; **p < 0.01. Scale bar, 100 mm. See also
Figure S5 and Tables S5 and S6.DISCUSSION
In thiswork,we show thatH&Nandesophageal SCCsescape the
antitumor activity of PI3Ka inhibition via upregulation of AXL and
consequent increase in AXL-EGFR interaction that, subse-
quently, initiates the PLCg-PKC signaling cascade. The activa-(F) Boxplot representation of tumor volume as a function of AXL levels quantified in patient tissue samples by
expressing on the left to low expressing on the right. For each group, the tumor volume distribution is represe
the middle line; the interquartile range (25%–75%), by the box; and the minimum and maximum, by the wh
(G) Changes in AXL levels following BYL719 treatment in three SCC patients. Pre, pre-treatment samples; Po
BYL719 therapy.
(H) Western blot with the indicated antibodies of whole cell lysates (WCL) or proteins immunoprecipitated wit
lines. EGF (50 ng/ml) was supplemented to the culture media 20 min prior to lysate collection. IgG, control
(I) Proximity ligation assay (PLA) of AXL and EGFR on parental and resistant cells. Quantification of AXL/EGFR
25 mm.
Data are presented asmeans ± SEM; p value was calculated using two-tailed Student’s t test. *p < 0.05; **p <
Cancer Cell 27, 533–tion of this pathway sustains mTOR activ-
ity in the presence of PI3K/AKT inhibition
and is prevented by direct inhibition of
either EGFR/AXL upstream or PKC down-
streamactivity. Recently,we reported that
residual mTOR activation upon PI3Ka in-
hibition is also sufficient to limit its anti-
tumor activity in breast cancer (Elkabets
et al., 2013), suggesting that this may be
a shared feature of PI3Ka resistance.
However, we suspect that the mecha-
nisms adopted by cancer cells to bypass
PI3K/AKT inhibition and maintain mTOR
activation are cancer lineage dependent.AXL is a ubiquitously expressed RTK that belongs to the TAM
family of receptors (including also TYRO and MER) (Graham
et al., 2014). When overexpressed, AXL is capable of transform-
ing fibroblasts and promoting xenograft growth of various human
cancers (Holland et al., 2005; Janssen et al., 1991). Moreover,
expression of AXL has been shown to induce resistance toIHC. Axl levels are split into three groups from high
nted by its statistics; the median is represented by
iskers.
st, samples collected at disease progression upon
h an anti-EGFR antibody (IP) from the indicated cell
immunoglobulin G.
complex was carried out using ImageJ. Scale bar,
0.01; ***p < 0.005. See also Figure S4 and Table S4.
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Figure 6. AXL/EGFR Complexes Activate mTOR via PLCg-PKC Signaling
(A) Western blot with the indicated antibodies of protein lysates from the indicated cell lines. S, BYL719 sensitive; R, BYL719 resistant.
(B)Western blot with the indicated antibodies of protein lysates fromCAL33R and KYSE180R cells treated for 4 hr with 5 mMof erlotinib (Erlo), with or without 1 mM
BYL719.
(C) Immunoprecipitation (IP) of EGFR1173 andwestern blot with the indicated antibodies of CAL33R treated for 4 hr with 1 mMR428.WCL, whole cell lysates. IgG,
control immunoglobulin G.
(D) Western blot with the indicated antibodies of protein lysates from KYSE180R cells treated for 4 hr with different PKC inhibitors (0.5 mM PKC412, 1 mM
Enzastaurin, 10 mM Go6967, 10 mM BIMVIII, 2 mM BIMI, 10 mM Go6983, and 5 mM Rottlerin) with or without 1 mM BYL719.
(legend continued on next page)
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Figure 7. Scheme Summarizing the Pro-
posed Mechanism by which AXL Drives
Resistance to PI3Ka in SCC
Upregulation of AXL and its interaction with EGFR
leads to PLCg-PKC activation via phosphorylation
of EGFR on tyrosine 1173. This results in sustained
mTOR activity upon PI3Ka suppression. Combi-
nation of PI3Ka inhibition with EGFR, AXL, or PKC
suppression would prevent this occurrence by
blocking the PLCg/PKC axis, resulting in superior
antitumor activity compared with monotherapy.targeted agents such as the EGFR/HER2 inhibitors lapatinib,
erlotinib, and cetuximab by re-activating the AKT, ERK, and
NF-KB pathways in breast, lung, and H&N cancers (Brand
et al., 2014; Giles et al., 2013; Liu et al., 2009; Zhang et al.,
2012). Here, we show that in cell lines, xenograft models, and tu-
mors from SCC patients treated with BYL719, AXL is upregu-
lated in primary and acquired resistant states.
In our models, AXL seems to induce a re-wiring of the EGFR
signaling toward the PLCg-PKC axis by receptor phosphoryla-
tion at tyrosine 1173. The specificity of this activation is under-
scored by the fact that either knockdown or pharmacological
inhibition of AXL was sufficient to decrease phosphorylation of
this residue in our models. This finding is in accordance with a
recent report showing increased phosphorylation of this tyrosine
residue in H&N cells with acquired resistance to cetuximab and
overexpressing AXL (Brand et al., 2014).
Based on our findings, it is also tempting to speculate that
other cancer types characterized by EGFR dependency, such(E) Western blot with the indicated antibodies of protein lysates from KYSE180R cells treated with PKC412
(F) Cell viability (4 days) of the indicated cell lines in the presence of 1 mM BYL719 and different concentratio
(G) Analysis of cell cycle (S-phase arrest) and cell survival (annexin V) in BYL719-resistant cells after 48 hr of tre
combination. Means of two independent experiments performed in duplicate per cell line are shown.
Data are presented as means ± SEM; p value was calculated using two-tailed Student’s t test. **p < 0.01. S
Cancer Cell 27, 533–5as colon or lung cancer, may adopt a
similar mechanism to escape PI3Ka inhi-
bition. Likewise, these tumors may be
exquisitely sensitive to dual PI3Ka and
EGFR suppression.
It remains to be elucidated whether
upfront treatment with dual PI3K and
EGFR inhibitors would avoid AXL overex-
pression and prevent or delay the emer-
gence of resistance. The combination of
BYL719 and cetuximab is currently being
tested in H&N cancer patients (A.R.A. Ra-
zak et al., 2014, J. Clin. Oncol., abstract).
Interim results from this pilot study were
recently presented, and a clinical benefit
rate of 28% (four partial responses and
five stable diseases out of 32 patients)
was reported. However, the presence of
PIK3CA alterations was not required for
patient enrollment (unlike the first-in-man
phase I clinical trial; D.J., H.A. Burris,
M. Schuler, J.H.M. Schellens, J. Berlin,R. Seggewiss-Bernhardt, M. Gil-Martin, A. Gupta, J.R., J. Taber-
nero, F. Janku, H. Rugo, D. Bootle, C. Quadt, C. Coughlin,
D. Demanse, L. Blumenstein, and J.B., 2014, Annals of Oncology,
abstract), and the statusofAXLexpression in these tumorshasnot
been reported.
In summary, our study indicates that an AXL-EGFR interaction
mediates resistance toPI3Ka inhibitionbyshiftingEGFRsignaling
toward the PLCg-PKC axis to maintain mTOR activity in a PI3K/
AKT-independent fashion. As a result, we propose simultaneous
EGFR and PI3Ka blockade as a potential therapeutic strategy to
prevent or delay the emergence of resistance to PI3Ka inhibitors
in patients with SCC of H&N and esophagus.EXPERIMENTAL PROCEDURES
Cell Lines and Chemical Compounds
All other cell lines were purchased from commercial vendors. For the entire list
of cell lines, see the Supplemental Experimental Procedures.and BYL719 as indicated.
ns of PKC412.
atment with 1 mMBYL719, 0.5 mMPKC412, or their
ee also Figure S6.
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CAL33R, LB771-HNCR, KYSE70R, and KYSE180R cells were obtained after
chronic exposure to increasing concentrations of BYL719 for 8 months. All
cells were maintained at 37C in a humidified atmosphere at 5% CO2. The
PI3Ka inhibitor, BYL719, was kindly provided by Novartis. The AXL inhibitor
R428, EGFR inhibitor erlotinib, MET inhibitor crizotinib, mTOR inhibitors
RAD001 and AZD8055, and PKC inhibitors were purchased from Santa
Cruz Biotechnology or Selleckchem.com. All compounds were dissolved in
DMSO for in vitro experiments.
Western Blotting and Immunoprecipitation
Cells were washed with ice-cold PBS and scraped into ice-cold RIPA lysis
buffer (Cell Signaling) supplemented with phosphatase inhibitor cocktails
(cOmplete Mini and PhosphoSTOP, Roche). Lysates were cleared by centrifu-
gation at 13,000 rpm for 10 min at 4C, and supernatants were removed and
assayed for protein concentration using the Pierce BCA Protein Assay Kit
(Thermo Scientific). For immunoprecipitation experiments, cells were lysed us-
ing lysis buffer (Cell Signaling #9803) and immunoprecipitated with anti-EGFR
antibodies bound to Protein A magnetic beads (Cell Signaling #8687) after in-
cubation overnight at 4C. The immunoprecipitate, and a sample of the initial
whole cell lysate for each condition, was then analyzed by western blot.
Thirty-five micrograms of total lysate was resolved on NuPAGE 4%–12%
Bis-Tris gels (Life Technologies) and electrophoretically transferred to Immobi-
lon transfer membranes (Millipore). Membranes were blocked for 1 hr in 5%
BSA in Tris-buffered saline (TBS)-Tween and then hybridized using the primary
antibodies in 5% BSA TBS-Tween. Mouse and rabbit horseradish peroxidase
(HRP)-conjugated secondary antibodies (1:50,000, Amersham Biosciences)
were diluted in 5% BSA in TBS-Tween. Protein-antibody complexes were de-
tected by chemiluminescence with SuperSignal West Femto Chemilumines-
cent Substrate (Thermo Scientific), and images were captured with a G-BOX
camera system.
Establishment of Tumor Xenografts and Studies in Nude Mice
Six-week-old female athymic NU/NU nudemice purchased fromCharles River
Laboratories were injected with 13 107 of KYSE180, KYSE180R, and CAL33.
5 3 106 HSC3, 5 3 106 A253, 5 3 106 HSC2, and 3 3 106 FaDu cells were in-
jected subcutaneously in 100 ml culture media/Matrigel (BD Biosciences) at a
1:5 ratio.
The patient-derived xenografts belong to Oncotest (http://www.oncotest.
com/tumor-models.html), and experiments were conducted at their site (fee
for service) in accordance with their institutional animal care and use
committee.
For cell-line-derived xenografts, animals were randomized at a tumor vol-
ume of 70 to 120 mm3, 2–4 weeks after injection. Animals were randomized
to four to six groups, with n = 8–10 tumors per group. Animals were orally
treated daily with BYL719 (25 mg/kg or 50 mg/kg in 0.5% carboxymethylcel-
lulose sodium salt [CMC]; Sigma). Mice were treated every 5 days with cetux-
imab (10 mg/kg) via intra-peritoneal injection.
Xenografts were measured with digital caliper, and tumor volumes were
determined with the formula: (length3width2)3 (p/6). At the end of the exper-
iment, animals were euthanized using CO2 inhalation. Tumor volumes are
plotted as means ± SEM.
Mice were maintained and treated in accordance with the institutional
guidelines of Massachusetts General Hospital and Memorial Sloan Kettering
Cancer Center. Mice were housed in air-filtered laminar flow cabinets with a
12-hr light/dark cycle and food and water ad libitum. Animal experiments
were approved by the institutional animal care and use committees from both
Massachusetts General Hospital andMemorial Sloan KetteringCancer Center.
Patients
Tumor response was assessed according to the RECIST criteria. All measur-
able lesions up to a maximum of five lesions per organ and ten lesions in total,
representative of all involved organs, were identified as target lesions, re-
corded and measured at baseline, and then followed throughout the study.
A sum of the longest diameter for all target lesions at baseline was used as
a reference by which the objective tumor response was characterized. Pre-
treatment biopsies were obtained within 2 weeks of starting the study agent.
Progression biopsies were performed at the time of disease progression.
These procedures were approved by the institutional review board of Massa-544 Cancer Cell 27, 533–546, April 13, 2015 ª2015 Elsevier Inc.chusetts General Hospital and by the ethical committee of the Vall d’Hebron
University Hospital. Informed consent was obtained from all subjects.
Secreted Protein Screen
The secretome screen was assessed as previously described (Harbinski et al.,
2012). Briefly, secreted protein library cDNAs were reverse transfected into
HEK293T cells with FuGENE HD (4:1 ratio transfection reagent to DNA) and
incubated for 4 days to allow accumulation of secreted proteins in superna-
tant. The supernatant was then transferred to CAL33 and SNU-1214 cells,
followed by addition of BYL719 to a final concentration of 3 mM. After 96 hr,
growth was measured using CellTiter-Glo.
Statistical Analysis
A two-way t test was conducted using GraphPad Prism (GraphPad Software).
Error bars represent the SEM. All the in vitro experiments were repeated at
least three times. Some in vivo experiments were run in duplicate, with at least
n = 6 for each treatment arm.
ACCESSION NUMBERS
The RNA-seq count data have been deposited in the Gene Expression
Omnibus database under accession number GSE61515.
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Supplemental Information includes Supplemental Experimental Procedures,
six figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2015.03.010.
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